Lymphedema is a progressive and chronic condition resulting from the accumulation of lymphatic fluid in the tissues of the body, causing swelling. Swelling results when the lymphatic system cannot effectively drain protein-rich fluid from the interstitium—a fluid-filled space between internal structures such as organs and muscles and the skin.

Lymphedema swelling may appear in different areas of the body, depending on the severity and advancement of the condition. The most frequently involved areas are the arms and legs, where fluid accumulation is typically most apparent. Lymphedema may, however, involve more sensitive or less conspicuous areas like the genitals, face, and neck. Sometimes the swelling can be in the wall of the chest or even the oral cavity itself, causing inconvenience and functional compromise. The place of swelling depends on the nature of the etiology—either primary or secondary lymphedema—and can actually have a deep impact on a patient's life.

Outside of physical pain and deformity, lymphedema frequently has psychological and social costs. Patients can suffer from pain, decreased mobility, and emotional distress because of swelling that is noticeable or because of ongoing therapy.

Primary vs. Secondary Lymphedema: What's the Difference?

Primary Lymphedema is uncommon and usually resultant from birth defects or genetic mutations in the lymphatic system. It occurs in about 1 out of 100,000 individuals.

Secondary Lymphedema is more prevalent, occurring in approximately 1 in 1,000 individuals in the U.S. It arises as a result of injury or blockage of lymph vessels by external factors, including:

• Cancer therapies (such as radiation or surgery)
• Infections
• Trauma
• Chronic venous insufficiency

Primary lymphedema is comparatively uncommon, occurring in about 1 in 100,000 people. It is a result of congenital or genetic malformations of the lymphatic system. Dr. Manokaran clarifies, "This condition can occur at birth, during puberty, or even later in adulthood. It usually happens without a visible cause but is based on the patient's genetic structure."

Diagnosis is generally based on careful patient history and sophisticated imaging procedures like lymphangiograms, lymphoscintigrams, or MR lymphangiograms, which provide visualization of structural defects in the lymphatic channels.

Treatment starts conservatively with manual lymphatic drainage (MLD), compression bandaging, and stringent skin hygiene to minimize fluid accumulation and prevent infections. For advanced cases, surgical interventions such as lymphovenous anastomosis (LVA) are options. "Microsurgical procedures such as LVA are game-changers for patients whose symptoms don't respond to conservative therapies," explains Dr. Manokaran.

Secondary lymphedema is much more prevalent, affecting about 1 in 1,000 individuals in the United States — frequently as a consequence of cancer therapy, infection, trauma, or surgery. "The etiology is widespread," states Dr. Manokaran, "from parasitic infection in the tropics to post-mastectomy swelling in breast cancer patients."

Infection-related cases can be managed initially with antibiotics and anti-inflammatory drugs. But when the condition is chronic, more aggressive interventions are required. These involve surgical removal of fibrotic tissue or advanced reconstructive techniques such as lymph node transfer or super microsurgery, especially when lymphatic function has been severely impaired.

Patient history continues to be a mainstay of diagnosis in secondary lymphedema, since knowledge of the precipitating event can influence the entire treatment strategy.

Symptoms of Lymphedema

Though caused by different factors, both forms of lymphedema share common symptoms, such as:

• Swelling in limbs or proximal regions such as the chest, genitals, and face
• Limited range of motion
• Heaviness and tightness of limbs
• Pain, changed sensations, and color changes in the skin

These symptoms can hinder daily functioning, so early identification is important. "Delayed treatment can lead to irreversible tissue damage," warns Dr. Manokaran.

Is Lymphedema Reversible?

Complete healing is still a pipedream, particularly in cases of advanced status. Still, in stage 1 (early-stage lymphedema), usually reversal is feasible through vigilant treatment. The intent is symptom management, diminishment of swelling, and forestalling progression of the disease.

Early detection is important. Those at risk — including cancer patients, those with a family history, or those in endemic areas — need to watch their bodies carefully and take preventative measures such as lymphatic massage and compression garments.

Management Strategies to Live with Lymphedema

Maintain Skin Integrity

Since lymphedema can impair skin health, daily skin care and moisturizing are very important. Even small cuts or scrapes can quickly become infected, so it's important to clean wounds immediately and apply sunscreen and insect repellent when in the sun.

Adopt Supportive Habits

Loose clothing, resting swollen extremities, and the avoidance of constrictive jewelry can all help alleviate discomfort. Proper sitting — with legs flat and the avoidance of leg crossing — can also facilitate smooth fluid movement. Compression wear for regular travelers, particularly by plane, is highly advisable.

Track Symptoms

A symptom diary assists both patients and practitioners in making adjustments to treatment programs. Be on the lookout for changes in swelling, coloration of the skin, or feelings.

Maintain Emotional Wellness

Chronic illness may have psychological consequences. Meeting with support groups or talking with a mental health professional can bring emotional relief and strengthen resilience. "Patients shouldn't underestimate the value of mental health care to treat lymphedema," asserts Dr. Manokaran.

Nourish the Body

A healthy, balanced diet packed with fruits, vegetables, and lean protein benefits the lymphatic system. A healthy intake of water maintains fluid balance in the body.

Although primary and secondary lymphedema are different in cause and treatment processes, both need early diagnosis, individualized treatment, and a multidisciplinary team approach. With greater awareness, patient activism, and improved medical and surgical procedures, living well with lymphedema is absolutely feasible.

Dr. G. Manokaran, MBBS, MS General Surgery, MCh Plastic Surgery at Apollo Spectra Hospital, Chennai in India

Wildfires are a big concern for US citizens. Since the beginning of 2025, 31,039 wildfires have consumed 1.3 million acres of US land, according to the National Interagency Fire Center. Wildfires are uncontrolled fires that burn wildland and often rural areas. These fires can exhaust forests, grasslands, and many other ecosystems. With the amount of smoke generated, wildfires can severely affect the health of people.

A new study suggests that wildfires might indirectly raise the risk of flu and COVID-19 outbreaks. The smoke from wildfires often forces people to stay indoors, and when more people are gathered in enclosed spaces, infectious diseases can spread more easily. This finding was recently published in the journal PLOS Climate.

Why Staying Inside Puts You at Higher Risk

When wildfires burn, the air outside gets filled with smoke, making people go indoors. This creates perfect conditions for illnesses like the flu to spread, as a researcher from Georgetown University explained. With more people packed together, germs can jump from one person to another more easily. But there's a simple way to lower this risk: just wearing a mask indoors can help a lot.

Following People's Movements During Wildfires

Researchers looked at mobile phone data to see where people went during wildfires. This data showed visits to over 4.6 million places across the U.S., both inside and outside. They focused on the wildfire season in Oregon and Washington in 2020. By checking air quality, they found the areas worst affected by smoke. During that time, especially in August and September 2020, widespread wildfires caused a lot of smoke in these states.

More People, More Risk

The study found a clear increase in indoor activities when the wildfires were burning. In counties across Oregon, indoor activity went up by 14%, and in Washington counties, it increased by almost 11%. Major cities also saw a significant jump: Seattle experienced a 16% rise, and Portland saw an 11% increase in people spending time indoors. This shift means more people were confined together.

Using computer models, the researchers confirmed that more people indoors raises the risk of infectious diseases spreading, especially for highly contagious illnesses like flu and COVID-19. But these models also showed that wearing masks indoors can help slow the spread. They found that even a small increase in mask wearing (just 10% more people) could lower the number of new cases during wildfires. In areas hit hardest by smoke, like parts of Oregon and Washington, more than half the people might need to wear masks to effectively control the disease.

Preparing for Health Risks in a Changing Climate

The researchers advise public health experts to be aware of this connection if wildfire smoke reaches their communities. They should also warn people about the higher risk of infection. The study emphasized that as we face more extreme weather events, our public health plans need to change. We have to address not just the direct environmental harm from wildfires, but also how people react and adapt to these emergencies. By understanding how people behave and planning for it, we can better protect everyone's health in a world where extreme events are becoming more common.

Being one of the most common cancer diagnoses, skin cancer claims more than two people every hour. The Skin Cancer Foundation also specifies that having five or more sunburns doubles your risk of melanoma, which is a type of skin cancer. Despite the fact that people are often urged to wear sunscreen and take protection from heat, one in five Americans will develop skin cancer by the age of 70. However, the survival rate of melanoma is 99 percent, meaning if people can get it diagnosed early, they can get proper treatment. So, how can one get an early diagnosis?

An experimental AI tool called PanDerm shows promising results in accelerating the detection of melanoma and other skin conditions, according to a new study published in Nature Medicine. When doctors used PanDerm, it improved the accuracy of skin cancer diagnoses by 11%, and the accurate diagnosis of other skin conditions by almost 17%.

Enhancing Clinical Decision-Making

PanDerm is made in a way to assist doctors by helping them understand complex imaging data and make more confident and informed decisions. While a lot of people are skeptical of the use of AI and how it may impact human lives in the long rn, the study shows that using it to work alongside professionals can help us reach great medical heights.

Researchers explained the tool is built to work alongside medical professionals, making it easier for them to interpret difficult images and choose the right course of action with greater certainty. This support is especially important because about 70% of people experience some kind of skin condition, making it crucial to spot them early for better treatment outcomes.

How PanDerm Works

Developed by a global research team, PanDerm was trained on a massive collection of over 2 million skin images, using four different types of medical imaging. Unlike previous AI models that struggled to combine various data types, PanDerm was specifically created to identify a wide range of skin conditions. It uses images from tiny microscopic slides to wide views showing lesions and the surrounding skin.

Researchers also said that by training PanDerm with diverse data from different imaging techniques, they've created a system that can understand skin conditions similar to how dermatologists do—by combining information from various visual sources.

Impressive Performance and Future Potential

In the study, PanDerm was tested on various tasks related to skin health, including screening for cancer, counting moles, tracking changes in lesions, and diagnosing a broad spectrum of skin conditions. The AI consistently delivered strong results, often needing only 5% to 10% of the data that doctors typically require for diagnoses. This means it can provide accurate results with much less information.

This AI tool could be especially valuable in areas where it's hard to see a dermatologist, as researcher Peter Soyer pointed out. However, the researchers stress that PanDerm needs more evaluation and real-world testing in different healthcare settings and with various types of patients before it can be approved and widely used.

Treatment For Skin Cancer

The Cancer Research UK explains that when you have skin cancer, the main treatment is usually surgery. However, depending on where the cancer is, how big it is, and your overall health, you might have a different kind of treatment. Your doctor will discuss all the possible options with you.

Besides surgery, other treatments include radiotherapy, which uses high-energy rays similar to X-rays to kill cancer cells, often for basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). You might also get a chemotherapy cream that uses strong drugs to destroy cancer cells, or Imiquimod cream (Aldara), which helps your body's own defenses fight the cancer.

For some types of skin cancer, doctors might suggest targeted drugs or immunotherapy. These treatments either attack specific parts of cancer cells or boost your immune system to help it kill the cancer. Another option is photodynamic therapy (PDT), which uses a special drug and light to destroy the cancer cells.

After you finish your skin cancer treatment, you'll need to have follow-up appointments to make sure everything is okay.

The U.S. Food and Drug Administration (FDA) approved Yeztugo, a powerful, long-acting injection developed by Gilead Sciences, as a twice-yearly preventive treatment against HIV. The move has ignited widespread hope among global health advocates, signaling what many believe to be the dawn of a new era in HIV prevention.

With a 99.9% success rate in preventing HIV transmission in clinical trials, this injectable therapy formally known as lenacapavir, offers a revolutionary alternative to daily pills and could dramatically reshape the global HIV landscape.

Why Is HIV Drug Approval Such a Big Deal?

For more than 40 years, HIV has eluded a vaccine. While treatment has transformed HIV into a manageable chronic condition for millions, preventing new infections has remained a formidable challenge. Daily oral PrEP (pre-exposure prophylaxis), such as Truvada, has helped, but adherence is difficult for many especially in vulnerable populations.

That’s where Yeztugo changes the game. Its unique mechanism, longevity, and ease of use have the potential to overcome the barriers of daily pill regimens. Administered once every six months by a healthcare provider, it’s the longest-lasting PrEP option ever approved.

“This is a historic day in the decades-long fight against HIV,” said Daniel O’Day, CEO of Gilead Sciences. “We believe this marks a turning point.”

How Does Yeztugo Work?

Lenacapavir is not a vaccine. Instead, it is an antiretroviral that blocks HIV from infecting immune cells and replicating. What sets it apart is its ability to stay in the body for extended periods, providing protection for six months with a single shot.

Gilead conducted two major trials to test the drug’s efficacy in over 2,000 cisgender women in sub-Saharan Africa, the injection showed 100% prevention of HIV infection.

A parallel trial involving men who have sex with men and gender-diverse individuals showed a 99.9% effectiveness rate, with only two breakthrough infections. These outcomes, published in The New England Journal of Medicine, led Science to name lenacapavir its 2024 “Breakthrough of the Year.”

Reported side effects were minimal, limited mostly to injection site irritation, headaches, and nausea.

How The New Drug Affects HIV Treatment And Prevention?

Interestingly, lenacapavir didn’t start as a preventive drug. It was initially approved in 2022 (under the brand name Sunlenca) for treating drug-resistant HIV.

Researchers at Gilead quickly recognized two features that made it ideal for prevention: its long half-life and its ability to disrupt multiple stages of the HIV life cycle.

“We saw a fantastic protective effect after just one injection—even in non-human primate studies,” said Tomas Cihlar, Gilead’s VP of Virology. “That’s when we realized we had to pursue prevention aggressively.”

Could This Replace HIV Vaccine?

In many ways, yes—at least for now. While lenacapavir isn’t a vaccine in the traditional sense, its efficacy closely mimics one. And since traditional HIV vaccine development has repeatedly hit roadblocks, some experts believe lenacapavir may be the next best thing.

“Lenacapavir used by itself for prevention is a huge breakthrough,” said Dr. David Ho of Columbia University, a pioneer in HIV research. “Its potential to curb the epidemic is enormous.”

Yet ironically, the drug’s success could make it harder to develop a conventional vaccine. Why? Because it would now be unethical to assign people a placebo in vaccine trials when such a highly effective alternative exists.

Is There A the Catch?

While the science is exciting, several real-world challenges could stand in the way of Yeztugo’s success, cost, access, and policy chief among them.

Previous injectable PrEP options like cabotegravir, approved in 2021, came with hefty price tags and have yet to make a meaningful global impact. Gilead has not yet announced pricing for Yeztugo, but there’s concern it may follow suit.

Additionally, logistical barriers remain. Yeztugo must be administered in a clinic by a healthcare provider and requires that recipients test negative for HIV before each shot. That’s a significant hurdle for high-risk individuals in low-resource settings.

“There’s huge promise here, but we’ve built a jet without a runway,” said Hui Yang of the Global Fund to Fight HIV, TB, and Malaria. “If we don’t address distribution, affordability, and systemic barriers, the science won’t matter.”

Who Gets Access To HIV Injection?

Gilead has signed royalty-free licensing deals with six manufacturers to produce lenacapavir generics in 120 low- and middle-income countries. But critics point out that many middle-income nations, such as some in Latin America, are left out.

Meanwhile, in the U.S., states with strong support for PrEP programs have already seen a 38% decline in HIV infections. In contrast, states without similar support saw a 27% increase, according to The Lancet HIV.

With Medicaid cuts looming and the Supreme Court considering a case that could overturn the requirement for insurers to cover PrEP without copays, the long-term reach of Yeztugo may be compromised.

“We could be standing on the verge of eliminating new HIV infections,” said Carl Schmid of the HIV+Hepatitis Policy Institute. “But without the right policies, this will remain a medical miracle out of reach for too many.”

What Comes Next In the HIV Battle?

Gilead is already working on a once-a-year formulation of lenacapavir to make prevention even more accessible. The Global Fund aims to reach two million new PrEP users in the next three years, and Yeztugo could be pivotal to that goal.

There’s also ongoing research into self-administered versions of the injection, which would help reduce the need for in-clinic visits—especially vital for reaching marginalized populations.

The FDA’s approval of Yeztugo is more than a regulatory milestone—it’s a paradigm shift in HIV prevention strategy. Whether this breakthrough can live up to its promise will depend on how quickly and equitably it can be delivered.